<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758458</url>
  </required_header>
  <id_info>
    <org_study_id>2586.00</org_study_id>
    <secondary_id>NCI-2012-02779</secondary_id>
    <secondary_id>2586</secondary_id>
    <secondary_id>2586.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01758458</nct_id>
  </id_info>
  <brief_title>Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma</brief_title>
  <official_title>Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best way to give laboratory treated&#xD;
      autologous T cells together with aldesleukin and to see how well it works in treating&#xD;
      patients with merkel cell carcinoma that has spread from the primary site (place where it&#xD;
      started) to other places in the body. Biological therapies, such as cellular adoptive&#xD;
      immunotherapy, may stimulate the immune system in different ways and stop tumor cells from&#xD;
      growing. Aldesleukin may stimulate the white blood cells to kill tumor cells. Giving cellular&#xD;
      adoptive immunotherapy with aldesleukin may be a better treatment for metastatic merkel cell&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and potential toxicities associated with treating patients with&#xD;
      metastatic merkel cell carcinoma (MCC) by combined myosin heavy chain (MHC) up-regulation&#xD;
      therapy and adoptive transfer of merkel cell polyomavirus (MCPyV) T-antigen (TAg)-specific&#xD;
      polyclonal autologous cluster of differentiation (CD)8+ T cells.&#xD;
&#xD;
      II. Determine the antitumor efficacy associated with treating patients with metastatic MCC by&#xD;
      combined MHC up-regulation therapy and adoptive transfer of MCPyV TAg-specific polyclonal&#xD;
      autologous CD8+ T cells.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the in vivo persistence and where evaluable, migration to tumor sites of&#xD;
      adoptively transferred polyclonal CD8+ T cells targeting the MCPyV TAg.&#xD;
&#xD;
      II. Determine the in vivo functional capacity of adoptively transferred polyclonal CD8+ T&#xD;
      cells targeting the MCPyV TAg.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo radiation therapy or recombinant interferon beta intralesional injection&#xD;
      within day -3 to day -1.&#xD;
&#xD;
      Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine&#xD;
      intravenously (IV) on day 1 and aldesleukin subcutaneously (SC) every 12 hours on days 1-14.&#xD;
      Treatment repeats at least every 28 days for up to 2 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with continued presence of detectable metastatic disease 8 weeks after the first&#xD;
      infusion may repeat the treatment regimen including radiation therapy or recombinant&#xD;
      interferon beta injection.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A Phase I/II study (NCT01758458) is now recruiting&#xD;
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence and nature of toxicity related to the study treatment assessed using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The treatment will be considered to have an acceptable safety profile if the observed toxicity rate is consistent with a true rate that does not exceed 30%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of response based on &quot;median time to new metastasis&quot;</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease response by RECIST criteria</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity of transferred T cells</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCC-specific survival</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of transferred T cells in blood and in tumor</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Recurrent Merkel Cell Carcinoma</condition>
  <condition>Stage IV Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (autologous T cells and aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.&#xD;
Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (autologous T cells and aldesleukin)</arm_group_label>
    <other_name>125-L-Serine-2-133-interleukin 2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>r-serHuIL-2</other_name>
    <other_name>Recombinant Human IL-2</other_name>
    <other_name>Recombinant Human Interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (autologous T cells and aldesleukin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (autologous T cells and aldesleukin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (autologous T cells and aldesleukin)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>RADIATION</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Interferon Beta</intervention_name>
    <description>Given intralesionally</description>
    <arm_group_label>Treatment (autologous T cells and aldesleukin)</arm_group_label>
    <other_name>Beta Interferon</other_name>
    <other_name>Betantrone</other_name>
    <other_name>Feron</other_name>
    <other_name>Human Interferon Beta</other_name>
    <other_name>Interferon Beta</other_name>
    <other_name>Interferon, Beta</other_name>
    <other_name>Interferon-B</other_name>
    <other_name>Interferon-beta</other_name>
    <other_name>Naferon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological documentation of MCC concurrent with the diagnosis of metastatic&#xD;
             disease&#xD;
&#xD;
          -  Evidence of MCPyV TAg tumor expression&#xD;
&#xD;
          -  Available peptide-MHC pair that can be folded into a tetramer for which MCPyV&#xD;
             TAg-specific cells can be generated and reactivity to cell lines expressing MCPyV TAg&#xD;
             with the corresponding human leukocyte antigen (HLA)&#xD;
&#xD;
          -  Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic&#xD;
             imaging (x-ray, computed tomography [CT] scan, positron emission tomography [PET]&#xD;
             scan, magnetic resonance imaging [MRI], or ultrasound)&#xD;
&#xD;
          -  At least 3 weeks must have passed since any of the following: systemic&#xD;
             corticosteroids, immunotherapy (for example, interleukins, MCC vaccines, intravenous&#xD;
             immunoglobulin, expanded polyclonal tumor infiltrating lymphocyte [TIL] or&#xD;
             lymphokine-activated killer [LAK] therapy), pentoxifylline, other small molecule or&#xD;
             chemotherapy cancer treatment, other investigational agents or other agents that&#xD;
             target merkel cell carcinoma&#xD;
&#xD;
          -  Cardiac ejection fraction &gt;= 40% (multigated acquisition [MUGA] or echocardiogram);&#xD;
             for patients with significant risk factors for coronary artery disease (CAD)&#xD;
             (including family history, hypertension, and/or dyslipidemia), or age &gt; 50, stress&#xD;
             echo or stress thallium testing is required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to generate antigen-specific MCPyV TAg-specific CD8+ T cells for infusions&#xD;
&#xD;
          -  Active infections prior to receiving study treatment or systemic infection requiring&#xD;
             chronic maintenance or suppressive therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 2&#xD;
&#xD;
          -  White blood cell (WBC) &lt; 2000/mcl&#xD;
&#xD;
          -  Hemoglobin (Hb) &lt; 8 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1000/mcl&#xD;
&#xD;
          -  Platelets &lt; 50,000/mcl&#xD;
&#xD;
          -  New York Heart Association functional class III-IV heart failure, symptomatic&#xD;
             pericardial effusion, stable or unstable angina, symptoms of coronary artery disease,&#xD;
             congestive heart failure, clinically significant hypotension, or an ejection fraction&#xD;
             of =&lt; 40 % (echocardiogram or MUGA)&#xD;
&#xD;
          -  Clinically significant pulmonary dysfunction, as determined by medical history and&#xD;
             physical exam; patients so identified will undergo pulmonary functions testing and&#xD;
             those with forced expiratory volume in one second (FEV1) &lt; 2.0 L or diffusing capacity&#xD;
             of the lung for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) &lt; 50% will be&#xD;
             excluded&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml/min which cannot be attributed to MCC metastasis&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Bilirubin &gt; 3 x ULN which cannot be attributed to MCC metastasis&#xD;
&#xD;
          -  Active autoimmune disease (e.g. systemic lupus erythematosus, vasculitis, infiltrating&#xD;
             lung disease, inflammatory bowel disease) whose possible progression during treatment&#xD;
             would be considered unacceptable by the investigators&#xD;
&#xD;
          -  Symptomatic and untreated central nervous system (CNS) metastasis; however, patients&#xD;
             with 1-2 asymptomatic, less than 1 cm brain/CNS metastases without significant edema&#xD;
             may be considered for treatment; if sub-centimeter CNS lesions are noted at study&#xD;
             entry, then a repeat imaging will be performed if more than 4 weeks have elapsed from&#xD;
             the last scan&#xD;
&#xD;
          -  Any condition or organ toxicity that is deemed by the principal investigator (PI) or&#xD;
             the attending physician to place the patient at unacceptable risk for treatment on the&#xD;
             protocol&#xD;
&#xD;
          -  Pregnant women, nursing mothers, men or women of reproductive ability who are&#xD;
             unwilling to use effective contraception or abstinence; women of childbearing&#xD;
             potential must have a negative pregnancy test within two weeks prior to entry&#xD;
&#xD;
          -  Clinically significant and ongoing immune suppression including, but not limited to,&#xD;
             systemic immunosuppressive agents such as cyclosporine or corticosteroids, chronic&#xD;
             lymphocytic leukemia (CLL), uncontrolled human immunodeficiency virus (HIV) infection,&#xD;
             or solid organ transplantation&#xD;
&#xD;
          -  Patients may not be on any other treatments for their cancer aside from those included&#xD;
             in the protocol; patients may not undergo another form of treatment concurrently with&#xD;
             this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aude Chapuis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <disposition_first_submitted>March 3, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 3, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 7, 2017</disposition_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Aude Chapuis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

